Literature DB >> 22032532

Management of recurrent hepatitis C infection after liver transplantation.

Alpna R Limaye1, Roberto J Firpi.   

Abstract

Recurrence of hepatitis C virus remains a near-universal phenomenon after liver transplantation (LT) and is responsible for the high morbidity and low survival seen in these patients. The severity of recurrent disease varies depending on multiple factors, only some of which are modifiable. Antiviral therapy is associated with improved outcomes, but viral clearance is only attainable in a small percentage of this patient population. This patient population is in need of new therapeutic options, and it remains to be seen whether direct-acting antiviral agents will be the answer to this ongoing therapeutic question. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22032532     DOI: 10.1016/j.cld.2011.08.003

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  2 in total

1.  Use of protease inhibitors in liver transplant recipients.

Authors:  Gary L Davis; Jacqueline G O'Leary
Journal:  Gastroenterol Hepatol (N Y)       Date:  2012-03

2.  Mycophenolate mofetil inhibits hepatitis C virus replication in human hepatic cells.

Authors:  Li Ye; Jieliang Li; Ting Zhang; Xu Wang; Yizhong Wang; Yu Zhou; Jinping Liu; Hemant K Parekh; Wenzhe Ho
Journal:  Virus Res       Date:  2012-06-21       Impact factor: 3.303

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.